IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 1 of 43  
 Clinical Study Protocol 
CM 2017- 01 
 
Phase 1  Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients with 
Unresectable Stage III or Stage IV Cutaneous Melanoma  
 
 
Protocol  Identifying Number:  CM 2017- 01 
Principal Investigator:  [INVESTIGATOR_38022], MD,  PhD 
IND Sponsor:  Morphogenesis,  Inc. 
Funded By: [CONTACT_38047], Inc. 
Draft/Version  Number:  Version 7; September [ADDRESS_39900] Number:                              03655756
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39901] OF  ABBREVIATIONS  ..................................................................................................................... 6 
STATEMENT OF  COMPLIANCE  ............................................................................................................. 8 
PROTOCOL  SUMMARY  ....................................................................................................................... 9 
SCHEMATIC OF  STUDY  DESIGN  .............................................................................................................. 10 
1. KEY ROLES  ................................................................................................................................ 11 
2. INTRODUCTION: BACKGRO UND INFORMATION AND  SCIENTIFIC  RATIONALE  .............................. 12 
2.1 Background Information  .................................................................................................... 12 
2.2 Rationale  .......................................................................................................................... 13 
2.3 Potential Risks  and Benefits  ............................................................................................... 13 
2.3.1.  Known  Potential  Risks  ................................................................................................ 13 
2.3.2.  Known  Potential  Benefits  ........................................................................................... 14 
3 OBJECTIVES AND  PURPOSE  ....................................................................................................... 14 
4 STUDY DESIGN  AND  ENDPOINTS  ............................................................................................... 14 
4.1 Description of the  Study  Design  ......................................................................................... 14 
4.2 Study  Endpoints  ................................................................................................................ 15 
4.2.1 Primary  Endpoint  ....................................................................................................... 15 
4.2.2 Secondary  Endpoints  .................................................................................................. 15 
4.2.3 Explor atory  Endpoints  ................................................................................................ 15 
5 STUDY ENROLLMENT  AND  WITHDRAWAL  .................................................................................. 16 
5.1 Participant  Inclusion  Criteria  .............................................................................................. 16 
5.2 Participant  Exclusion  Criteria  ............................................................................................. 17 
5.3 Strategies for Recruitment  and Retention  .......................................................................... 17 
5.4 Participant Withdrawal  or Termination  .............................................................................. 17 
5.4.1 Reasons for Withdrawal  or Termination  ..................................................................... 17 
5.4.2 Handling of Participant Withdrawal  or Termination ..................................................... 18 
5.5 Premature Termination or Suspension of Study  .................................................................. 18 
6 STUDY  AGENT  ........................................................................................................................... 18 
6.1 Study  Agent(s)  Description  ................................................................................................ [ADDRESS_39902] Storage  and Stability  ..................................................................................... 19 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 3 of 43  
 6.1.4 Preparation ............................................................................................................... 19 
6.1.5 Dosing  and Administration ......................................................................................... 21 
6.1.6 Route  of Administration  ............................................................................................. 21 
6.1.7 Starting Dose and Dose  Escalation  Schedule  ................................................................ 21 
6.1.8 Dose  Adjustments/Modifications/Delays  ....................................................................... 21 
6.1.9 Duration of Therapy  ................................................................................................... 21 
6.1.10  Tracking  of Dose  ........................................................................................................ 21 
6.2 Study Agent  Accountability  Procedures  .............................................................................. 21 
7 STUDY PROCEDURES  AND  SCHEDULE  ........................................................................................ 22 
7.1 Study  Procedures/Evaluations  ........................................................................................... [ADDRESS_39903]- of-care  Study  Procedures  ............................................................................ 22 
7.2 Laboratory  Procedures/Evaluations  ................................................................................... 22 
7.2.1 Clinical Laboratory  Evaluations  .......................................................................................... 22 
7.3 Study  Schedule  .................................................................................................................. 23 
7.3.1 Screening  ................................................................................................................... 23 
7.3.2 Enrollment  / Baseline  .................................................................................................  24 
7.3.3 Optional Study Visits (for multiple dose  cycle  only)  ..................................................... 24 
7.3.4 Final Study  Visit  ......................................................................................................... 26 
7.3.5 Early  Termination Visit  ............................................................................................... 26 
7.3.6 Unscheduled Visit  ...................................................................................................... 27 
7.3.7 Schedule of  Events  Table  ............................................................................................ 27 
7.4 Concomitant Medications, Treatments,  and Procedures  ..................................................... 30 
8 ASSESSMENT OF SAFETY ................................................................................................................ 30 
8.1 Specification of  Safety  Parameters  ............................................................................................ 30 
8.1.1 Definition of Adverse  Events  (AE)  ................................................................................ 31 
8.1.2 Definition of Serious Adverse  Events  (SAE) .................................................................. 31 
8.1.3 Definition of  Unexpected Adverse Drug  Experience  ..................................................... 31 
8.2 Classification of an Adverse  Event  ...................................................................................... 32 
8.2.1 Severity  of Event  ........................................................................................................ 32 
8.2.2 Relationship to  Study  Event  ........................................................................................... 32 
8.2.3 Expectedness  ............................................................................................................. 33 
8.3 Time Period and Frequency of Event Assessment  and Follow -up ......................................... 33 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 4 of 43  
 8.4 Reporting  Procedures  ............................................................................................................ 33 
8.4.1 Adverse  Event Reporting  ............................................................................................ 33 
8.4.2 Serious Adverse  Event  Reporting  ................................................................................ 34 
8.4.3 Unexpected Adverse Drug Experience Problem  Reporting  ........................................... 34 
8.4.4 Reporting  of Pregnancy  .............................................................................................. 34 
8.5 Study  Halting  Rules  ........................................................................................................... 34 
8.6 Safety Oversight  ................................................................................................................ 35 
9 CLINICAL  MONITORING ................................................................................................................. 35 
10 STATISTICAL  CONSIDERATIONS .................................................................................................. 35 
10.1 Statistical and Analytical  Plans  ........................................................................................... 35 
10.2 Statistical  Hypotheses  ............................................................................................................ 35 
10.3 Analysis  Dataset(s)  ............................................................................................................ 36 
10.4 Description of  Statistical  Methods  ..................................................................................... 36 
10.4.1  General  Approach  ...................................................................................................... 36 
10.4.2  Safety  Analyses  .......................................................................................................... 36 
10.4.3  Baseline  Descriptive  Statistics ..................................................................................... 36 
10.4.4  Planned Interim  Analyses  ........................................................................................... 36 
10.4.5  Exploratory  Analyses  .................................................................................................. 37 
10.5 Sample Size .......................................................................................................................  38 
11 SOURCE DOCUMENTS AND ACCESS TO  SOURCE  DATA/DOCUMENTS  ...................................... 38 
12 QUALITY ASSURANCE AND  QUALITY  CONTROL  ...................................................................... 38 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ........................................................................... [ADDRESS_39904]  .................................................................................................  39 
13.3 Informed  Consent  Process  .................................................................................................  39 
13.3.1  Consent/Assent and Other Informational Documents Provided  to Participants  ............. [ADDRESS_39905]  KEEPI[INVESTIGATOR_1645]  ............................................................................... 40 
14.1 Data Collection and Management  Responsibilities  ............................................................. 40 
14.2 Study  Records  Retention  ................................................................................................... 41 
14.3 Protocol  Deviations  ........................................................................................................... 41 
14.4 Publication and Data  Sharing  Policy  ................................................................................... 41 
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39906]  POLICY  .............................................................................................. 42 
17 LITERATURE REFERENCES  ...................................................................................................... 43 
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39907] OF ABBREVIATIONS  
Abbreviation  Definition  
AE(s)  Adverse  Event(s)  
AGE  Agarose Gel Electrophoresis  
ANOVA  Analysis of Variance  
APC Antigen Presenting Cells  
aPTT  activated Partial Thromboplastin  Time  
BOR  Best Overall Response  
CBC Complete Blood  Count  
CD Cluster of Differentiation  
CFR Code of Federal Regulations  
CMP  Comprehensive Metabolic  Panel  
CR Complete  Response  = complete regression  of all lesions 
CRA Clinical Research  Associate  
CRF(s)  Case Report  Form(s)  
CT Computed  Tomography  
CTCAE  Common  Terminology  Criteria for Adverse  Events 
CTLA -4 Cytotoxic T -Lymphocyte -Associated Protein 4 
DCR Disease Control  Rate 
DLT Dose -limiting  Toxicity  
DM Data Management  
DMF  Drug Master  File 
EBV Epstein -Barr Virus  
ECG Electrocardiography  
ECOG  Eastern  Cooperative  Oncology  Group 
eCRF(s)  electronic Case Report  Form(s)  
E. coli Escherichia coli  
EtBr  Ethidium Bromide (DNA  stain)  
FTA Fluorescent Treponemal  Antibody  
GAPDH  Glyceraldehyde  3-Phosphate  Dehydrogenase 
GCP Good Clinical Practice  
HBV  Hepatitis B Virus  
HCV  Hepatitis C  Virus  
HEK293T  Human Embryonic Kidney cells 
HIV Human Immunodeficiency  Virus  
HLA Human Leukocyte  Antigen  
HTLV  Human T Lymphotropic Virus 1 & 2 
ICH International Confe rence on  Harmonisation  
ICMJE  International Committee  of Medical Journal  Editors 
IHC Immunohistochemistry  
IFx-Hu2.0  pAc/emm55  DNA  plasmid  combined  with  in vivo-jetPEI® in  the presence of glucose  
INFγ  Interferon  Gamma  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39908] to Follow  Up 
MCB  Master Cell Bank  
MHC  Major Histocompatibility  Complex  
MM  Medical Monitor  
NED  No Evidence of  Disease  
OD Optical Density  
ORR  Overall (Objective) Response Rate  
OS Overall Survival  
pAc/ emm55  DNA  plasmid  encoding the emm55  gene  
pAc/empty  pAc/emm55  DNA  plasmid  without  the emm55  gene 
PBRS  Peachtree Bioresearch Solutions,  Inc. 
PBS Phosphate Buffered  Saline  
PCR Polymerase Chain  Reaction  
PD Progressive  Disease  = ≥ 20%  increase  in tumor  burden 
PD-1 Programmed Cell Death Protein  1 
PE Phycoerythrin  
PET Positron Emission  Tomography  
PFS Progression -Free Survival  
PI [INVESTIGATOR_38023] = ≥ 30% decrease in tumor  burden  
QC Quality Cont rol 
RAB-AP01 Anti-Emm55 Rabbit Polyclonal Antibody  
RECIST  v1.1  Response  Evaluation  Criteria in Solid  Tumors  version  1.1 
RPR Rapid Plasmin  Reagin  
RTPCR  Reverse Transcriptase  Polymerase  Chain  Reaction 
SAE(s)  Serious Adverse  Event(s) 
SC Subcutaneous  
SCB Starter Cell Bank  
SEM  Standard Error of the  Mean  
SD Stable  Disease  = % change  in tumor  burden  is between  -30%  and +20% 
SOP Standard Operating  Procedure  
S. pyogenes  Streptococcus pyogenes 
SumL  Sum of the Longest  Diameters  
TCR T Cell Receptor  
TE 10 mM Tris-Cl, pH 8.0, 1 mM Ethylenediaminetetraacetic  acid 
TEAE(s)  Treatment- emergent adverse  event(s)  
UP(s)  Unexpected Adverse Drug Experience 
VCOG  Veterinary  Cooperative  Oncology  Group 
WCB  Working Cell Bank  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 8 of 43  
 STATEMENT OF COMPLIA NCE 
The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on the 
Protection of Human Subjects (45 CFR Part 46). The Principal Investigator [INVESTIGATOR_38024], or changes to the protocol will take place without prior agreement from the sponsor and 
documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an 
immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection  Training.  
I agree to ensure that all staff members involved in the conduct of this study are informed about their 
obligations in meeting the above  commitments.  
 
 
 
 
 
Principal Investigator:     
 
 
[INVESTIGATOR_7496]:    Date:     
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 9 of 43  
 PROTOCOL SUMMARY  
Title  Phase 1 Study Using a Plasmid DNA Coding for Emm55 
Streptococcal Antigen in Patients with Unresectable Stage III or 
Stage IV Cutaneous Melanoma  
Short Title  pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma  
Protocol Number  Melanoma 2017 -01 
Phase  Phase 1  
Methodology  Non -randomized, open -label, uncontrolled  
Study Duration  Approximately 1 year  
Study Center(s)  Single -center  
Objectives  Primary: To assess safety and feasibility  
Secondary:  To assess any antitumor response  
Number of Subjects  Six 
Diagnosis and Main Inclusion  
Criteria  Male or female, confirmed stage III or stage IV unresectable  
melanoma with lesions accessible for intralesional injection  
Study Product, Dose, Route, 
Regimen  Plasmid DNA encoding a Streptococcal antigen in a cationic 
polymer -based solution in doses of 100 µg delivered 
intralesionally at a single time point “Week 0” with a maximum 
of three lesions injected.  The primary endpoint (DLT) will be  
assessed at 4 weeks.  
Optional dosing  After primary endpoint has been met (DLT), at the 
investigator’s  discretion in consultation  with the sponsor, 
patients may receive  
additional doses on a 3 -week cycle.  
Follow -up - Primary  Week 4; Day 28+/ -7 business days.  
Follow -up – Optional.  21 days +/- [ADDRESS_39909] dose administered.  
Follow -up – Long -term  Obtain O S/subsequent treatments  for melanoma after MCC 
[ZIP_CODE] as of 11/1 6/2020 for all patients  with clinical response if 
available . 
Study Procedures  Six patients will receive IFx -Hu2.0 on an outpatient basis at a 
single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be 
injected). These patients will be assessed for any immediate 
adverse reactions and at Week 4 (Day 28+/ -7 business days) for 
any delayed adverse events.  
 
After the primary endpoint has been met (DLT), patients may 
receive additional doses on an optional [ADDRESS_39910] reported patients  
experiencing reactions such as mild fever, skin reactions, sweats 
and chills, which are often described as “flu -like” symptoms.  
Reference Therapy  None  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 10 of 43  
 Statistical Methodology  The data analysis is described to assess the safety of the 
injection of the study agent in six patients The intention -to-treat 
approach will be used for response to treatment data analysis of 
this trial (secondary objective). The exploratory testing will 
be mainly descriptive in this pi[INVESTIGATOR_38025]-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 11 of 43  
 SCHEMATIC OF STUDY DESIGN  
 
 
 
 
Screening 
 
  
 
 
 
 
 
 
 
Visit 1 (Week 0)  
   
 
    
 
Visit 2 (Week 4) -Final-  
  
 
 
Note: If patient consents to additional treatment, this may be performed every three weeks with a 21 - 
day foll ow-up visit.  
 
 
Informed consent eligibility, Physical exam w/vitals, 
Medical history, Concomitant meds, Clinical labs, ECG, 
Tumor sample/biopsy for immune response assays, CT 
and/or PET scan, Performance Status, Tumor Burden 
(lesion measurements)  
 
 
Physical exam w/vitals, Concomitant meds, AEs/SAEs, IFx -Hu2.0 
dosing, Blood for Immune Response Evaluation(baseline), Clinical 
labs, Performance Status, Tumor Burden  
 
 
 
 
Physical exam w/vitals, Concomitant meds, AEs/SAEs, 
Clinical labs, ECG, Blood for Immune Response Evaluation, 
Tumor sample/biopsy for histology and IHC, CT and/or PET 
scan, Performance Status, Tumor Burden  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39911]  
Tampa, FL [ZIP_CODE]  
T: 813- 875-6600  
E: PLawman@morphogenesis -inc.com  
 
Principle  Investigator  Joseph Markowitz, MD,  PhD 
Medical Oncologist; Assistant Member- Department of Cutaneous Onc . 
H. Lee Moffitt Cancer Center [ADDRESS_39912] 
Tampa, FL [ZIP_CODE]  
T: 813- 745-4673  
E: [EMAIL_635]
 
 
Clinical Laboratory  Clinical Pathology  Laboratory  
H. Lee Moffitt Cancer Center 
[ADDRESS_39913] 
Tampa, FL [ZIP_CODE]  
T: 813- 745-[ADDRESS_39914] 
Tampa, FL [ZIP_CODE]  
T: 813- 745-[ADDRESS_39915], Bldg,  100 
Marietta, GA [ZIP_CODE]  
T: 678- 373-[ADDRESS_39916]  
Marietta, GA 3006 8 
         T: [PHONE_609] 
 
Secondary Statistician for  
exploratory correlative data:       Youngchul Kim,  PhD 
H. Lee Moffitt Cancer Center 
[ADDRESS_39917] 
Tampa, FL [ZIP_CODE]  
T: 813- 745-4673  
 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 13 of 43  
 2. INTRODUCTION:  BACKGROUND INFORMATION  AND  SCIENTIFIC 
RATIONALE  
2.[ADDRESS_39918] be carried out for an effective anticancer immune response to occur (Chen and Mellman 2013). 
These events must be initiated, allowed to proceed and then to expand. In the first step of this process 
neoantigens created by [CONTACT_38048] (APC), a process that must be accompanied by [CONTACT_38049]. W e plan to optimize cancer immunity by [CONTACT_38050].  
Emm55 is a serotypi[INVESTIGATOR_38026] (S. pyogenes ) and is highly antigenic (Glikin and Finocchiaro 2014, Ra miya, Jerald et al. 2014). 
Intralesional injection of a novel plasmid DNA vaccine expressing the Emm55 protein derived from S. 
pyogenes showed clinical efficacy in an equine metastatic melanoma (Ramiya, Jerald et al. 2014). By 
[CONTACT_14662] a bacterial (foreig n) antigen, it is possible to expose ‘self’ tumor antigens and overcome tolerance 
to them, regardless of their number or uniqueness. This can be done by [CONTACT_38051]/ emm55 
plasmid into tumor cells ex vivo and administering the resultant ‘personaliz ed’ whole -cell vaccine as an 
intradermal injection. It is also possible to create a ‘personalized’ vaccine by [CONTACT_38052]/ emm55 
plasmid DNA directly into a patient’s lesion. In this way, an immune response is initiated to the 
neoantigens relevant to each individual patient without the difficulties involved in developi[INVESTIGATOR_38027].  
The product being tested in this clinical study, IFx -Hu2.0, is a plasmid DNA, pAc/ emm55 , formulated with 
in vivo -jetPEI®, a cationic polymer that aid s in cellular uptake of DNA, will be administered by [CONTACT_38053]. IFx -Hu2.0 is a cancer immunotherapy that stimulates the immune system to fight cancer. When 
introduced into a patient’s tumor cells, pAc/ emm55 drives expression of the highly imm unogenic Emm55 
protein in the cytoplasm and on the surface of the tumor cells. In this protocol, IFx -Hu2.0 will be utilized 
as a monotherapy in a feasibility study prior to combining it with checkpoint blockade.  
Cancer immune evasion transpi[INVESTIGATOR_38028]: 1) immune surveillance fails to recognize the 
alterations and abnormalities of tumors and 2) tumors take advantage of inhibitory pathways which are 
hardwired into the immune system for avoiding autoimmunity (Chen and Mellman 2013). Surface 
expr ession of the Emm55 antigen through intralesional injection of pAc/ emm55 engages the patient’s 
immune system and thwarts the tumor’s ability to evade surveillance by [CONTACT_38054] - 
specific tumor antigens and activating a wide array of naïve T cells.  
IFx-Hu2.[ADDRESS_39919] been no reported side effects associated with this therap y. However, when breaking tolerance to tumor - 
associated antigens, which are ‘self’ antigens, there is a possibility of inducing some form of  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39920] human innate immunity (Nitsche -Schmitz, 
Rohde et al. 2007). Due to high variability at the N -terminal region of M proteins, there have been more 
than [ADDRESS_39921] group A Streptococcal- mediated strep throat and suppurative skin diseases (Dale, 
Smeesters et al. 2017). However, some M proteins bind collagen and may cause side effects such as acute 
rheumatic fever in humans through molecular mimicry of collagen (Dinkla, Nitsche - Schmitz et al. 2007). 
Emm55, though, has been shown not to bind collagen due to the conformational influences of flanking 
sequences (Reissmann, Gillen et al. 2012). In the IFx -Hu2.0 vaccine, the Emm55 protein acts as an 
immunolog ic priming antigen aimed at attracting the patient’s immune system to tumor  cells.  
The product being tested in this clinical study, IFx -Hu2.0, is designed to exploit the inherent vulnerability 
of specific differences from patient to patient, lesion to lesion, and cell to cell. Regardless of the degree of 
complexity of an individual’s antigenic signature, this truly  patient -specific approach capi[INVESTIGATOR_38029]. By [CONTACT_38055]55 gene 
from S. pyogenes into a patient’s tumors by [CONTACT_38056], the highly immunogenic Emm55 
protein is expressed on tumor cells and initiates an immune cascade leading to the activation of multiple 
immune cells, including cytotoxic T cells. However, optimal T cell responses may be abrogated by [CONTACT_38057].  The 
interplay between antigen presentation/T cell activation and T cell suppression is critically  important in 
determining the outcome of immunotherapeutic interventions. The goal of this study is to determine th e 
feasibility of providing the IFx -Hu2.[ADDRESS_39922] been no reported side effec ts associated with this therapy. However, when breaking tolerance to tumor - 
associated antigens, which are ‘self’ antigens, there is a possibility of inducing some form of autoimmunity. Patients receiving other cancer vaccine therapi[INVESTIGATOR_38030], skin 
reactions, sweats and chills, tachypnea and hypotension. However, the effectiveness and side effects of 
immunotherapi[INVESTIGATOR_38031] e IFx -Hu2.0.  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39923] of intralesional injections of pAc/ emm55 has been evaluated in horses 
with malignant melanoma, in C57BL/6 B16 tumor- bearing mice and companion animals with various types 
of cancers. Whether the plasmid DNA was formulated with water, TE buffer or in vivo -jetPEI® or injected 
with a tuberculin syringe and needle or a needleless injector, the study results support the hypothesis that 
pAc/ emm55 , when injected into tumor lesions in vivo , is expressed as an immunogenic Emm55 protein 
that stimulates a multi -pronged immune attack on tumor cells that is clinically beneficial. Further, no 
adverse events were reported in any of the 200+ animals receivi ng intralesional  or intranodal injections 
of pAc/ emm55 plasmid DNA. Based on the results of these studies, Morphogenesis believes that 
pAc/ emm55 may have significant antitumor activity and will be well tolerated in human patients with  
melanoma.  
 
3 OBJECTIVE S AND  PURPOSE 
3.1 Primary  Objective  
Safety; i.e., to assess the safety, tolerability, and feasibility of vaccination with IFx -Hu2.0 as a monotherapy 
in patients with unresectable stage III or stage IV cutaneous melanoma.  
3.2 Secondary  Objective(s)  
The secondary objectives include the evaluation of response rate and assessment of the antitumor 
immune responses induced by [CONTACT_38058] -Hu2.0 in patients treated with this vaccine.  
 
4 STUDY DESIGN AND ENDPOINTS  
4.1 Description of the Study  Design  
 
Six male and/or female ad ult patients (greater than or equal to 18 years old), of any ethnicity and race, 
with unresectable stage III or stage IV cutaneous melanoma with accessible lesions, will be eligible for 
enrollment and treatment with IFx- Hu2.0. Pediatric melanoma is quite r are and the National Cancer 
Institute estimates that approximately [ADDRESS_39924] one form of systemic anti -PD-1-based immunotherapy as well as 
BRAF inhibition, if BRAF V600 mutated.  
Talimogene laherparepvec (IMLYGIC®) is indicated for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Therefore, patients with unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after initial 
surgery must have failed, refused or been deemed not candidates for talimogene laherparepvec to be 
eligible for this study.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 16 of 43  
 Enrollees will receive IFx -Hu2.0 at a single time point. Depending on the number of accessible lesions, a 
patient could receive up to three doses across three lesions (one dose per lesion). Forty millilters of 
peripheral blood will be collected from these patients prior to treatment administration and at the follow -
up visit four weeks later. The target dose will be [ADDRESS_39925], the maximum number of lesions to be injected at any given time 
point in the study phase proposed is three lesions. These samples will be used to perform complete blood 
counts (CBC) and clinical chemistry tests. A urine sample will be obtained for urinalysis for protein and 
blood at the same frequency. Blood samples will be drawn for immune response evaluation as well. 
Peripheral blood collections, and where feasible, as determined by  [CONTACT_976], tumor biopsies may be obtained on 
the first and subsequent treatment cycles.  At the end of the study period a biopsy of the lesion injected 
and a non -injected lesion (if applicable) will be collected. At the discretion of the PI [INVESTIGATOR_38032], the patient will have the option of continuing the study at three -week intervals so long as 
the subject under study has not  progressed.  
4.2 Study  Endpoints  
 
4.2.1 Primary  Endpoint  
 
The primary endpoints of this trial will be the safety and feasibility of the treatment regimen. Safety will 
be reported using Common Terminology Criteria for Adverse Events (CTCAE) version5.0. Feasibility will be 
defined as the ability to treat at least five of the six patients enrolled without dose- limiting toxicity (DLT).  
4.2.2 Secondary  Endpoints  
 
The secondary endpoint consists of observing and monitoring objective response rates and, although not 
needed for the conclusion of this study, progression -free survival (PFS) will also be recorded  when 
indicated.  Patients  who  consent to additional injection  cycles  will be observed  for toxicity  over  time.  
4.2.[ADDRESS_39926] one injectable lesion and one lesion for biopsy at study conclusion. Lymphocyte count  ≥ 
500,000 cells/mL 
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 
5. Willing and able to give writt en, informed  consent  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39927] be less than or equal to grade 1 adverse event levels for the parameters tested as defined by [CONTACT_3989]  v5.0: 
o Bone Marrow  Function  
▪ HGB = <LLN -  10.0 g/dL; <LLN - 6.2 mmol/L; <LLN - 100 g/L 
▪ WBC = <LLN -  3000/mm3; <LLN - 3.0 x  10
9/L 
▪ PLT = <LLN - 75,000/mm3; <LLN - 75.0 x  109/L 
o Coagulation  Parameters  
▪ INR = >[ADDRESS_39928]  
▪ aPTT = >ULN - 1.[ADDRESS_39929]  
o Renal  Function  
▪ Creatinine = >ULN - 1.[ADDRESS_39930]  
o Liver  Function:  
▪ Bilirubin = >ULN -  1.[ADDRESS_39931]  
▪ ALT = >ULN -  3.[ADDRESS_39932]  
▪ AST = >ULN -  3.[ADDRESS_39933]  
▪ ALP = >ULN - 2.[ADDRESS_39934]  
▪ GGT = >ULN -  2.[ADDRESS_39935] 
5.2 Participant Exclusion  Criteria  
 
1. Known brain metastases greater than 1 cm at  screening.  
2. Life expectancy of fewer than three months  
3. Prior systemic  anti-cancer  treatment  within  three weeks  from  start  of treatment (Day  0) 
4. Current  treatment with  systemic  immunosuppressive  corticosteroid  (greater  than  10 mg of daily 
prednisone) doses or other immunosuppressants such as those needed for solid organ 
transplants. Medications needed to treat conditions such as reactive airway disease are not 
excluded.  
5. Pregnant or lactating  women  
6. Presence of any uncontrolled  and significan t medical  or psychiatric  condition  which  would 
interfere with trial safety  assessments  
7. Treatment with  any investigational product  within  the three  weeks  preceding injection  
8. Immunizations  for encapsulated  bacteria were  not given  for patients  who  have  undergone  a 
splenectomy.  
9. Serious underlying medical or psychiatric conditions, active infections requiring the use of 
antimicrobial drugs,  or active  bleeding that would  make  the subject  unsuitable  or unable  to 
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39936]. An investigator may terminate participation in the study if:  
• Any clinic al adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant.  
• The participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study  participation.  
5.4.2 Handling  of Participant  Withdrawal  or Termination  
 
Every effort will be made to undertake protocol -specified safety follow -up procedures to capture AEs,  
serious adverse events (SAEs), and unexpected adverse drug experi ence. Participant replacement will be 
permitted at the discretion of the Principal Investigator (PI).  
5.[ADDRESS_39937]  (IRB)  
and will provide  the reason(s) for  the termination  or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to  participants  
• Demonstration of AEs or SAEs that would warrant  stoppi[INVESTIGATOR_007]  
• Insufficient compliance with protocol  requirements  
• Data that are not sufficiently complete and/or  evaluable  
• Determination of futility  
The study may resume once concerns about safety, protocol compliance, and data quality are addressed and satisfy the sponsor, IRB and/or the Food and D rug Administration (FDA) . 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 19 of 43  
  
6 STUDY  AGENT  
6.1 Study Agent(s)  Description  
 
6.1.1 Acquisition  
 
The manufacture of the drug substance (pAc/ emm55 ) plasmid DNA will be conducted at Aldevron (Fargo, 
North Dakota). The mixing of the Investigational Product compo nents (plasmid DNA, cationic polymer  and 
glucose)  for this Phase  [ADDRESS_39938] is manufactured as a vaccine kit containing three vials; Vial [ADDRESS_39939], IFx -Hu2.0.  
 
 
Component  Description  Purpose  
Plasmid DNA Mammalian expression plasmid containing emm55 gene 
(pAc/ emm55 ) in TE buffer (0.5 mg/mL)  Drug substance  
 
Cationic Polymer  Polyplus -transfection in vivo -jetPEI® cationic polymer 
(0.72 mg/mL)  Excipi[INVESTIGATOR_841]; cellular 
uptake of plasmid 
DNA 
 
Glucose   
5% Dextrose solution, USP  Excipi[INVESTIGATOR_841]; DNA-  
polymer complex 
stability  
 
6.1.[ADDRESS_39940] intralesional injection using a 
vaccine kit that contains; (1) Vial 1 -pDNA (drug substance), (2) Vial 2 - cationic polymer (excipi[INVESTIGATOR_841]), and  
(3) Vial 3 -glucose (excipi[INVESTIGATOR_841]). These components will be provided by [CONTACT_38059] <797> guidelines for single -dose containers. When possible, the preparation 
should be performed in an ISO 5/Class [ADDRESS_39941]  accompanying Certificates  of Analysis.  
1. Incubate kit at room temperature (RT) for [ADDRESS_39942] clinical 
pharmacy  procedures,  and then  draw  up 0.1 mL of Vial 3 into a ½ mL tuberculin  (TB) syringe 
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39943]  solution  into 
Vial 2 using the same technique described in Steps 3 &  4 
6. Vortex  Vial 1 & Vial 2 individually  at the “8” setting  for five seconds,  if this step  is performed 
outside  of the ISO 5 environment  wipe  vial septum  with  alcohol as performed  in Step  3 
Note : This is a CRITICAL step to ensure complexes form properly  
7. Using  a new  ½ mL TB syringe,  provided  with  kit, draw  up 0.[ADDRESS_39944]  contents  into 
Vial 1 using the same technique described in Steps 3 &  4 
8. Gently vortex Vial 1 using the same technique described in Step  6 
9. Allow  to incubate  at room  temperature for 15 minutes;  the mixed  solution  is stable  for [ADDRESS_39945]  is now  ready  for intralesional  administration  using a TB syringe,  supplied 
at the clinical pharmacy, at a dose of 0.2  mL/lesion  
11. The used  vials  should  be placed  in the designated  biohazard  bag,  provided  in the kit, and 
returned to  Morphogenesis  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 21 of 43  
  

IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 22 of 43  
 6.1.5 Dosing and  Administration  
 
The target dose will be 100 µg of plasmid DNA per lesion injected at a final dose volume of 0.2 mL per 
lesion. The maximum number of lesions to be injected at any given time point in the study phase proposed 
is three lesions.  
6.1.6 Route of  Administration  
 
Intralesional injections using 1 mL tuberculin syringes.  
6.1.7 Starting  Dose  and Dose  Escalation  Schedule  
 
The dose/lesion treated will be constant through this study: [ADDRESS_39946], one, two, or three lesions would be injected at a  time.  
The subjects will receive I Fx-Hu2.0 at a single time point as a monotherapy. These patients will then be 
observed for any dose -limiting toxicity or adverse events for up to four weeks. The maximum number of 
lesions to be injected in this study is three lesions.  
6.1.8 Dose  Adjustments/Modi fications/Delays  
 
No dose adjustments or modifications will be part of this study phase. However, the protocol will allow 
for delays of up to 7 business days to accommodate participant clinic visit rescheduling due to any 
unforeseen circumstances.  
6.1.9 Duration of Therapy  
 
Participants enrolled in the study will receive IFx -Hu2.0 at a single time point. After primary endpoint 
has been met (DLT), at the investigator ’s discretion in consul tation with the sponsor, patients may 
receive additional doses on a [ADDRESS_39947] mixing involves the drug substance (pAc/ emm55 plasmid DNA in TE 
buffer) with the remaining components; cationic polymer and glucose. This mixing of the final Investigational Product components will occur at the clinical site pharmacy. Once the final Investigational 
Product is pre pared, patient -specific labeling will be affixed showing two unique identifiers. Any excess 
product will be de -identified and returned to Morphogenesis for laboratory studies.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 23 of 43  
 7 STUDY PROCEDURES AND   SCHEDULE  
7.1 Study  Procedures/Evaluations  
 
7.1.1 Study -specific  Procedures  
 
• Medical history through interview and/or medical records  review  
• Medication  history  to include  current  prescription  and over -the-counter  medications;  a review 
of current  medications  will be part of the assessment  of eligibility  
• Physical examination  
• Radiographic or other imaging assessments  (photographs)  
• Biological specimen  collection  and laboratory  evaluations;  blood  draws  and urine  collections  will 
be made at each of the clinical visits in addition to tissue tumor tissue collection for research 
purposes.  
• A discussion  of the results  of any study -specific  procedures  will be provided  to the participant  
• Assessment of adherence to study requirements and  instructions  
• Collection of data on gender, race and  ethnicity  
7.1.[ADDRESS_39948]- of-care Study  Procedures  
 
Subjects will receive IFx- Hu2.0 as a monotherapy at a single time point and will be assessed for a period 
of four weeks. Once the four -week period expi[INVESTIGATOR_38033]/safety assessments have been 
completed, these patients will transition into standard -of-care or clinical trial protocols as determined by 
[CONTACT_978] [INVESTIGATOR_38034]. If the patient comes off study, PFS will need to be censored, but the time to 
first progression will be obtained during subsequent follo w-up with the patient’s consent. If the patient 
has a response to therapy, the patient will have the option of continuing the study at three -week intervals 
at the discretion of the PI [INVESTIGATOR_38035]. In this setting, PFS will be measured in the 
traditional way. Where feasible, as determined by [CONTACT_976], tumor biopsies and peripheral blood collections may 
be obtained on subsequent treatment  cycles.  
7.2 Laboratory  Procedures/Evaluations  
 
7.2.1 Clinical Laboratory  Evaluations  
• Hematology: (Complete Blood Count -  CBC) hemoglobin, hematocrit, white blood cells (WBC) 
with  differential count,  platelet  count,  blood  clotting  tests;  prothrombin  time  (PT) and activated 
partial thromboplastin time  (aPTT)  
• Biochemistry  (Comprehensive  Metabolic  Profile  - CMP):  glucose,  calcium,  albumin,  total  protein, 
sodium, potassium, CO2, chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate deh ydrogenase 
(LDH), Thyroid tests (TSH and  FT4)  
• Urinalysis: UA with microscopic  evaluation  
• Serum  pregnancy  test,  done  within  [ADDRESS_39949]  
• Human leukocyte antigen (HLA)  typi[INVESTIGATOR_38036]-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 24 of 43  
 • Serology  screening for HBV,  HCV,  HIV, HTLV,  EBV and T. pallidum  (RPR);  fluorescent  treponemal 
antibody absorption (FTA -ABS), if  necessary  
• Immunodeficiency  Panel  
• Anti-double -stranded DNA (anti -dsDNA) antibody  test 
• Anti-DNase B Titer,  Serum  
7.3 Study  Schedule  
 
7.3.1 Screening  
 
Screening Visit (Day -36 to - 1) 
• Obtain  informed  consent  of potential  participant  verified  by [CONTACT_38060].  
• Verify inclusion/exclusion  criteria.  
• Review medical  history  to determine eligibility  based  on inclusion/exclusion  criteria.  
• Review medications  history  to determine  eligibility  based  on inclusion/exclusion  criteria.  
• Record Concomitant  Medications.  
• Perform  medical examinations  needed  to determine  eligibility  based  on inclusion/exclusion 
criteria.  
• CT as clinically  indicated  and/or  PET scan.  Photographs  may  be utilized  for melanoma confined 
to the skin.  
• Electrocardiogram  (ECG)  
• Collect blood/urine  for: 
o Hematology: CBC -  hemoglobin, hematocrit, white blood cells (WBC) with differential 
count,  platelet  count;  blood  clotting  tests:  prothrombin  time  (PT) and activated  partial 
thromboplastin time  (aPTT)  
o Biochemistry: CMP -  glucose, calcium, albumin, total pro tein, sodium,  potassium, CO2, 
chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), 
Thyroid tests (TSH and FT4)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregnancy test:  done within [ADDRESS_39950] 
administration  
o Human leukocyte antigen (HLA)  typi[INVESTIGATOR_007]  
o Serology  screening for HBV,  HCV,  HIV, HTLV,  EBV and T. pallidum  (RPR);  fluorescent 
treponemal antibody absorption (FTA -ABS), if  necessary  
o Immunodeficiency  Panel  
o Anti-double -stranded DNA (anti -dsDNA) antibody  test 
o Anti-DNase B Titer,  Serum  
• Where feasible, as determined by [CONTACT_976], research study biopsy for histology  and/or immune 
response  assays  may  be collected  at the screening visit or the baseline  visit.  PI [INVESTIGATOR_38037].  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 25 of 43  
 o In the setting  of known melanoma,  archival tumor  tissue  may  be utilized  to confirm  the 
diagnosis (Moffitt or from external  source).  
o In this case,  two 4-micron  slices  (positive  charged  slides,  air dry overnight).  are required 
for research IHC experiments under the direction of [CONTACT_38084].  
o The H&E stained slide from the biopsy may be digitally  scanned.  
o For all portions of this protocol, fresh research biopsies will be obtained using a punch 
or shave biopsy technique. These samples will be placed in PBS or formalin and utilized 
for research purposes. The portion of the tissue divided for the PBS portion will be flash 
frozen  and utilized  for downstream  assays.  [CONTACT_38085]  will assess  whether  the tumor 
is of adequate size to split into two parts (PBS and  formalin).  
• Assessment and recording of ECOG Performance  Status.  
• Assessment and recor ding of Tumor Burden (lesion  measurements).  
• Schedule  study  visits  for participants  who  are eligible  and available  for the duration  of the study.  
• Provide  participants  with  general study procedures  and instructions  for clinical  visits  
7.3.2 Enrollment /  Baseline  
 
Enrollment/Baseline  Visit  (Visit  1, Day 0) 
• Obtain  demographic  information,  medical  history,  medication  history,  alcohol and tobacco  use 
history.  
• Record Concomitant  Medications.  
• Record vital signs, results of physical examination, other assessments.  
• Collect blood/urine  for: 
o Hematology:  CBC - hemoglobin,  hematocrit,  white  blood  cells  (WBC)  with  differential 
count, platelet  count  
o Biochemistry: CMP -  glucose, calcium, albumin, total protein, sodium, potassium,  CO2, 
chloride, BUN, creatinine,  total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase  (LDH)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregnancy test: done within [ADDRESS_39951]. Joseph 
Markowitz, including immune response baseline  evaluation.  
• Where feasible,  as determined  by [CONTACT_976], research  study  biopsy  for histology  and/or  immune 
response  assays may  be collected  at the screening visit or the baseline  visit.  
• Administer the Investigational  Product.  
• Assessment and recording of ECOG Performance  Status  
• Assessment and recording of Tumor Burden (lesion  measurements)  
• Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989]  v5.0  
7.3.3 Optional  Study  Visits  (for multiple  dose  cycle  only ) 
 
(Week 4 Day 28 +/ -7 business days)  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 26 of 43  
 • Record vital signs, results of physical examination,  other assessments  
• Collect blood/urine  for: 
o Hematology:  CBC - hemoglobin,  hematocrit,  white  blood  cells  (WBC)  with  differential 
count, platelet count; blood clotting tests: prothrombin time (PT), activated partial 
thromboplastin time  (aPTT)  
o Biochemistry: CMP -  glucose, calcium, albumin, total protein, sodium,  potassium, CO2, 
chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase  (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH); 
thyroid tests: (TSH and  FT4)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregnancy test: done within [ADDRESS_39952]. Joseph 
Markowitz, including immune response  evaluation.  
• Optional  research  study  biopsy  for histology  and immune  response  assays  may  be collected.  
• Administer the Investigational  Product.  
• Assessment and recording of ECOG Performance  Status  
• Assessment and recording of Tumor Burden (lesion  measurements)  
• Assessment and recording of Concomitant  Medications  
• Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989]  v5.0  
• CT as clinically  indicated  and/or  PET scan  (photographs  may  be utilized  for melanoma confined 
to the skin)  
(Week 7 Day 49 +/ -7 business days)  
• Record vital signs, result s of physical examination,  other assessments  
• Collect blood/urine  for: 
o Hematology:  CBC - hemoglobin,  hematocrit,  white  blood  cells  (WBC)  with  differential 
count, platelet  count  
o Biochemistry: CMP -  glucose, calcium, albumin, total protein, sodium,  potassium, CO2, 
chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase  (LDH)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregnancy test: done with in [ADDRESS_39953]. Joseph 
Markowitz, including immune response  evaluation.  
• Optional  research  study  biopsy  for histology  and immune  response  assays  may  be collected.  
• Administer the Investigational  Product.  
• Assessment and recording of ECOG Performance  Status  
• Assessment and recording of Tumor Burden (lesion  measurements)  
• Assessment and recording of Concomitant  Medications  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 27 of 43  
 • Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989]  v5.0  
7.3.4 Final Study  Visit  
 
(Week 4 Day 28 +/ -7 business days for Single Dose Cycle ) 
 
OR 
(Week 21 +/ - [ADDRESS_39954] dose for Multiple Dose Cycle ) 
• Record vital signs, results of physical examination  
• Collect blood/urine  for: 
o Hematology:  CBC - hemoglobin,  hematocrit,  white  blood  cells  (WBC)  with  differential 
count, platelet count; blood clotting tests: prothrombin time (PT), activated partial 
thromboplastin time  (aPTT)  
o Biochemistry: CMP -  glucose, calcium, albumin, total protein, sodium,  potassium, CO2, 
chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH); 
thyroid tests: (TSH and  FT4)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregnancy test  
o Anti-double -stranded DNA (anti -dsDNA) antibody  test 
o Anti-DNase B Titer,  Serum  
o [ADDRESS_39955]. Joseph 
Markowitz, including immune response  evaluation.  
• Tumor  sample biopsy  of injected  lesion  for histology  and immune  response  assays  
• Biopsy of non -target lesion (if applicable)  
• Assessment and recording of ECOG Performance  Status  
• Assessment and recording of Tumor Burden (lesion  measurements)  
• Assessment and recording of Concomitant  Medications  
• Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989] v5.0  
• CT as clinically  indicated  and/or  PET scan  (photographs  may  be utilized  for melanoma confined 
to the skin)  
 
Overall  Survival Status:  Long Term Follow -up   
• On 11/1 6/2020  (± 4 weeks) , the survival status and subsequent anti -cancer therapy since last being 
seen on trial will be obtained  from the EMR . Subsequent therapi[INVESTIGATOR_38038] (immune -based therapy, chemotherapy, radiation, surgery) with clinical 
response if available.   
7.3.5 Early Termination  Visit  
 
• Record vital signs, results of physical examination  
• Collect blood/urine  for: 
o Hematology:  CBC - hemoglobin,  hematocrit,  white  blood  cells  (WBC)  with  differential 
count, platelet count; blood clotting tests: prothrombin time (PT), activated partial 
thromboplastin time  (aPTT)  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 28 of 43  
 o Biochemistry: CMP -  glucose, calcium, albumin, total protein, sodium,  potassium, CO2, 
chloride, BUN, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH); 
thyroid tests: (TSH and  FT4)  
o Urinalysis: UA with microscopic  evaluation  
o Serum pregna ncy test  
o Anti-double -stranded DNA (anti -dsDNA) antibody  test 
o Anti DNAse B Titer,  Serum  
o [ADDRESS_39956]. Joseph 
Markowitz, including immune response  evaluation.  
• Tumor  sample biopsy  of injected  lesion  for histology  and immune  response  assays  
• Biopsy of non -target lesion (if applicable)  
• Assessment and recording of ECOG Performance  Status  
• Assessment and recording of Tumor Burden (lesion  measurements)  
• Assessment and recording of Concomitant  Medications  
• Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989]  v5.0  
• CT as clinically  indicated  and/or  PET scan  (photographs  may  be utilized  for melanoma confined 
to the skin)  
7.3.6 Unscheduled  Visit  
 
• Record vital signs, results of targeted physical examination as  indicated.  
• Collect  blood/urine/research  biopsies  as indicated,  at the discretion  of the Investigator.  
• Assessment and recording of Concomitant  Medications  
• Observation  and recording  of adverse  or serious  adverse  events  as defined  by [CONTACT_3989]  v5.0  
• Assessment and recording of ECOG Performance  Status  
  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 29 of 43  
  
7.3.7 Schedule of Events  Table  
 
Schedule of Events Table  
Schedule of Events: ( Single dose cycle scenario ) 
Procedure  Screening  
(Day -36 to - 1) Week 0  
(D=0)  Week 4**  
(D=28)*  Unscheduled 
visit  Early 
Termination  
Visit  Long -term 
Follow -up1 
Informed consent 
eligibility  X     X 
Physical exam w/vitals  X X X X X  
Medical history  X   X X X 
Concomitant meds.  X X X X X  
AEs/SAEs  X X X X X  
IFx-Hu2.0 dosing   X     
Blood for Immune 
Response  
Evaluation   X X X X  
***Clinical labs        
CBC, CMP  X X X X X  
LDH X X X X X  
Blood clotting tests 
(PT/PTT)  X  X  X  
HLA typi[INVESTIGATOR_007]  
(if not previously  
reported)  X      
EBV ab  X      
Hepatitis B and C, 
HTLV -1 & 2  X      
HIV, RPR (FTA if 
necessary)  X      
Thyroid Tests (Free T4, 
TSH)  X  X  X  
Serum Pregnancy Test  X X X  X  
Immunodeficiency 
Panel  X      
Urinalysis  X X X X X  
Anti-double -stranded 
DNA  
(anti -dsDNA)  X  X  X  
Anti-DNAse B Titer 
Serum  X  X  X  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 30 of 43  
 ECG X      
Optional Tumor 
sample/biopsies for 
immune  
response assays  X X X X X  
Optional Tumor  
sample/biopsies for 
histology  X  X X X  
CT and/or PET scan 
(Photographs may be utilized for melanoma 
confined to the  
skin)  X  X  X  
Performance Status  X X X X X  
Tumor Burden (lesion  
measurements)  X X X X X  
Confirmation of 
histology by [CONTACT_38061] 
(may use archival  
tissue)  X      
Overall Survival       X 
* +/-7 business days; **Final study visit; ***Screening labs may be performed within 7 days of treatment.  
 
1 A long- term follow -up on 11/16/2020 (± 4 weeks) that includes the survival status and subsequent anti -
cancer therapy since last  being seen on trial will be obtained from the EMR. Subsequent therapi[INVESTIGATOR_38039] (immune -based therapy, chemotherapy, radiation, surgery) with 
clinical response if available . 
  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 31 of 43  
 Schedule of Events: (optional multiple dose cycle scenario, sample schedule for 3 cycles)  
Procedure  Screening  
(Day -36 
to -1) Week 0 
(D=0)  Week 4 
(D=28)*  Week 7 
(D=49)*  visit ([ADDRESS_39957] dose  Unscheduled 
Visit  Early 
Term Visit  Long -term 
Follow -up1 
Informed consent 
Eligibility  X       X 
Physical exam 
w/vitals  X X X X X X X  
Medical history  X     X X X 
Concomitant 
meds.  X X X X X X X  
AEs/SAEs  X X X X X X X  
IFx-Hu2.0 dosing  X X X     
Blood for Immune 
Response 
Evaluation   X X X X X X  
***Clinical labs          
CBC, CMP  X X X X X X X  
LDH X X X X X X X  
Blood clotting 
tests  
(PT/PTT)  X  X  X  X  
HLA typi[INVESTIGATOR_007]  
(if not previously 
reported)  X        
EBV ab  X        
Hepatitis B and C, 
HTLV -1 & 2  X        
HIV, RPR  
(FTA if necessary)  X        
Thyroid Tests 
(Free T4, TSH)  X  X  X  X  
Serum Pregnancy 
Test  X X X X X X X  
Immunodeficiency 
Panel  X        
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE]  
Confidential  Page 32 of 43  
 Urinalysis  X X X X X X X  
Anti-double -
stranded DNA 
(anti - dsDNA)  X  X  X  X  
Anti-DNAse B Titer 
Serum  X  X  X  X  
ECG X        
Optional Tumor 
sample/biopsies 
for immune 
response assays  X X X X X X X  
Overall Survival         X 
* +/-7 business days; **Final study visit; ***Screening labs may be performed within 7 days of treatment.  
 
1 A long- term follow -up on 11/16/2020 (± 4 weeks) that includes the survival status and subsequent anti -
cancer therapy since last being seen on trial will be obtained from the EMR. Subsequent therapi[INVESTIGATOR_38039] (immune -based therapy, chemotherapy, radiation, surgery) with 
clinical response if available . 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 33 of 43  
 7.4 Concomitant  Medications,  Treatments,  and Procedures  
 
All concomitant prescription medications taken during study participation will be recorded on the case 
report forms (CRFs). For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licensed clinician. Medications to be reported in the CRF are 
concomitant prescription medications, over -the-counter medications, and  non-prescription 
medications.   
 
[ADDRESS_39958] access to a copy of the CTCAE v5.0. Careful 
evaluation to determine the toxicity of IFx-Hu2.0 as a monotherapy will be performed. Adverse events will 
be documented beginning at initiation of treatment (Day 0) and continue at each visit detailed in the study 
treatment schema until progression, loss to follow -up, withdrawal of consent, or death. Subjects with 
treatment- related toxicity will be followed for the ongoing drug -related adverse events until resolved, 
return to baseline, deemed irreversible by [CONTACT_38062], or until the subject is lost to 
follow up, w ithdrawal of study consent, removal of the subject from the trial by [CONTACT_38063], or start of a subsequent anti -cancer therapy.  
8.1.1 Definition of Adverse Events  (AE)  
An AE is defined as any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.32 (a)).  
An ongoing  or intermittent  adverse  event  should  be recorded  only  once,  with  the highest/worst grade 
reported for the event. This study will utilize the Common Terminology Criteria for Adverse Events 
version 5 (CTCAE v5) for toxicity  
and adverse event reporting. A copy of the CTCAE v 5 can be downloaded from the CTEP home page  
http://ctep.cancer.gov/reporting/ctc.html.  
8.1.2 Definition of Serious Adverse Events  (SAE)  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the 
investigator or sp onsor, it results in any of the following outcomes:  
• death  
• life-threatening 
o An adverse event or suspected adverse reaction is considered “life -threatening” if, in 
the view of either the investigator or sponsor, its occurrence places the patient or 
subject  at immediate risk of death. It does not include an adverse event or suspected 
adverse  reaction  that,  had it occurred  in a more  severe  form,  might  have  caused  death.  
• inpatient hospi[INVESTIGATOR_10909]  
• results  in a persistent or significant  incapacity  or substantial  disruption  of the ability  to conduct 
normal life  functions  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 34 of 43  
 • a congenital anomaly/birth defect in the offspring of a  subject  
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, 
they  may  jeopardize  the patient  or subject  and may  require  medical or surgical  intervention  to 
prevent  one of the outcomes  listed  in this definition.  Examples  of such  medical events  include 
allergic  bronchospasm  requiring  intensive  treatment in an emergency  room  or at home,  blood 
dyscrasias  or convulsions  that do not result  in inpatient  hospi[INVESTIGATOR_059],  or the development  of 
drug dependency or drug abuse.  
For reporting purposes, also consider the occurrences of pregnancy or overdose (regardless of adverse 
outcome) as events which must be reported as important medical events. All Grade [ADDRESS_39959] be reported within 24 hours of the site becoming aware of 
the event, with follow- up reporting of outcome with the exception of grade 4 and 5 myelosuppression 
(including anemia, neutropenia, and thrombocytopenia that does not require hospi[INVESTIGATOR_059]).  
 
8.1.3 Definition of Unexpected Adverse Drug  Experience 
An unexpected adverse drug experience (UP) is defined by [CONTACT_4760] “any adverse drug experience, 
the specificity or severity of which is not consistent with the current investigator brochure. or, if  an 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 35 of 43  
 investigator brochure  is not required  or available,  the specificity  or severity  of which  is not consistent 
with the risk information described in the general investigational plan or elsewhere in the current 
application, as  amended”.  
This study will use the FDA definition of UP.  
8.2 Classification of an Adverse  Event  
 
8.2.1 Severity of  Event  
 
All AEs will be assessed by [CONTACT_38064]- NCI-DCTD -CTEP CTCAE v. 5.0, published: June 14, 2010.  
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity:  
• Mild  – Events  require  minimal or no treatment and do not interfere  with  the participant’s  daily 
activities.  
• Moderate  – Events  result  in a low level  of inconvenience  or concern  with  the therapeutic 
measures. Moderate events may cause some interference with  functioning.  
• Severe – Events  interrupt  a participant’s  usual  daily  activity  and may  require  systemic  drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  
8.2.2 Relationship to Study  Event  
 
The clinician’s assessment of an AE’s relationsh ip to IFx -Hu2.[ADDRESS_39960] their relationship  to study  
agent  assessed.  To help  assess,  the following  guidelines  are used.  
• Definitely Related –  There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test 
result, occurs in a plausible time relationship to study intervention administration and cannot be 
explained by [CONTACT_9153]. The response to withdrawal of the 
study intervention (dechallenge) should be clinically plausible. The event must be 
pharmacologically  definitive,  with  use of a satisfactory  rechallenge  procedure  if necessary.  
• Probably Related –  There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a 
reasonable time after administration of the study intervention, is unlikely to be att ributed to 
concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on 
withdrawal (dechallenge).  Rechallenge  information  is not required  to fulfill this definition.  
• Possibly Related –  There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition , other 
concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as  appropriate.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 36 of 43  
 • Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose 
temporal relationship to study intervention administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administration of the 
study intervention) and in which other drugs or chemicals or underlying disease provides plausible  
explanations  (e.g.,  the participant’s  clinical condition,  other  concomitant  treatments).  
• Not Related –  The AE is completely independent of study intervention administration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an 
alternative, definitive etiology documented by [CONTACT_15370].  
8.2.[ADDRESS_39961] emic reactions not meeting the criteria for SAEs will be captured on the appropriate 
CRF. Information to be collected includes an event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_38065] a 
diagnosis), and time of resolution/stabilization of the event. All AEs occurring during the study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
Any medi cal condition that is present at the time the participant is screened will be considered as baseline 
and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the  
study.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require doc umentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_38040]. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last 
visit. Events will be followed for outcome information until resolution or stabilization.  
8.4 Reporting  Procedures  
 
8.4.1 Adverse Event  Reporting  
 
All adverse events will be documented and reported to the FDA in the annual report.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 37 of 43  
 8.4.2 Serious Adverse Event  Reporting  
 
The study clinician will complete an SAE Form within the following timelines:  
• All SAEs,  regardless  of relationship,  will be recorded  on the SAE Form  and submitted  to the study 
sponsor within 24 hours of site  awareness.  
All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested by [CONTACT_38066]. The study sponsor will be responsible 
for notifying FDA of any unexpected fatal or life -threatening suspected adverse reaction as soon as 
possible but in no case later than 7 calendar days after the sponsor's initial recei pt of the information.  
8.4.3 Unexpected Adverse Drug Experience Problem Reporting  
Incidents or events that meet the FDA criteria for UPs require the creation and completion of a UP report 
form. It is the site investigator’s responsibility to report UPs to their IRB and to the study sponsor. The UP 
report will include the follo wing information:  
• Protocol  identifying information:  protocol  title and number,  PI’s name,  and the IRB project 
number  
• A detailed description of the event, incident, experience, or  outcome  
• An explanation  of the basis  for determining that the event,  incident,  experience,  or outcome 
represents a  UP 
• A description  of any changes  to the protocol  or other  corrective  actions  that have  been  taken  or 
are proposed in response to the  UP. 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
• UPs that are SAEs  will be reported  to the IRB and to the study  sponsor  within  24 hours  of the 
investigator becoming aware of the  event.  
• Any other  UP will be reported  to the IRB and to the study  sponsor  within  [ADDRESS_39962] the investigator immediately if they 
suspec t they might be pregnant (e.g., missed or late menstrual period) at any time during study 
participation.   
 
8.5 Study Halting  Rules  
 
Adm inistration of study agent will be halted when two grade -3 or greater AEs determined to be “possibly” 
or “probably” related are reported. The clinical team will notify the PI, the Peachtree Bioresearch 
Solutions, Inc. (PBRS) Medical Monitor (MM), and the Sponsor’s designated Drug  Safety Unit immediately 
when a second grade 3 event is reported, and the site will stop accepting new study participants. The PI [INVESTIGATOR_38041]’s designated Drug Safety Unit within 24 hours of thi s occurrence 
and will provide both with AE listing reports. The PBRS  MM will provide  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 38 of 43  
 recommendations for proceeding with the study to the clinical team and study sponsor. The study sponsor 
will inform the FDA of the temporary halt and the disposition of the study.  
8.6 Safety  Oversight  
 
Safety oversight will be under the direction of the PBRS MM and the Sponsor’s designated Drug Safety 
Unit. The PBRS MM reviews and evaluates safety and/or efficacy data on an ongoing basis to ensure the 
safety of patients and the validity and integrity of data. The PBRS MM reviews SAEs, deviations, Interim 
analysis and final report forms, and can make the following determinations, Accepted, Acceptable with Corrective Action and Tabled. The PI [INVESTIGATOR_38042] a statistical report of the study’s progress and summary of adverse events and deviations based on the phase of the study and the associated risk of the study as 
often as is  applicable.  
 
[ADDRESS_39963] of the 
trial is in compliance with the currently approved protocol/amendment(s), with good clinical practice 
(GCP), and with applicable regulatory  requirements.  
The PI [INVESTIGATOR_38043] -related documents, including the Investigator’s Study File (ISF ) and patient 
Case Report Forms (CRFs). All CRF entries will be made into paper CRFs provided by [CONTACT_38067] 
(EMR). The patient CRFs will be sec ured in a locked office in the Cutaneous Research Department. The 
review of medical records will be done in a manner to assure that patient confidentiality is maintained.  
Regulatory documents will be reviewed and CRFs will be monitored by [CONTACT_38068] (CRA) according to PBRS Standard Operating Procedures (SOPs). Monitoring will be performed 
regularly for accuracy, completeness, and 100% source data verification, validation of appropriate 
informed consent process, reporting of SAEs, and adherence to the protocol, Good Clinical Practice (GCP) 
guidelines, and all applicable regulatory  requirements.  
To ensure adherence to the protocol, monitoring reports will be submitted to the sponsor according to 
the timelines specified in the PBRS Gl obal Monitoring Plan.  
 
10 STATISTICAL  CONSIDERATIONS  
10.1 Statistical and Analytical  Plans  
 
The statistical and analytical plan was developed to assess safety in six patients.  
10.2 Statistical  Hypotheses  
 
IFX-Hu2.0 may be given safely to patients with unresectable stage III/IV melanoma.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 39 of 43  
 10.3 Analysis  Dataset(s)  
 
Safety Analysis Dataset: the subset of participants for whom safety analyses will be conducted (e.g., 
participants who took at least one dose of Investigational Product).  
10.4 Description of  Statistical  Methods  
 
10.4.1  General  Approach  
 
This is a feasibility study that is designed to evaluate the safety and the feasibility of IFx -Hu2.0 as a 
monotherapy in preparation for a combination trial with Keytruda® (pembrolizumab) for the treatment 
of unresectable stage III/IV metastatic melanoma. Safety will be assessed and reported based upon CTCAE 
v5.[ADDRESS_39964]. This will include immunolog y assessments to include but not 
limited to: quantity of effector T cells in the circulation and expression of the Emm55 protein within the 
tumor tissue. The data analysis of exploratory laboratory correlative endpoints will be descriptive.  All study resu lts will be preliminary and exploratory in nature due to the relatively small sample size of the  
trial.  
The data analysis will mainly be descriptive. The intention -to-treat approach will be used for response to 
treatment data analysis of this trial. Patien ts who are lost to follow -up or drop out of the study for any 
reason prior to their scheduled Final Study Visit will be censored for any time -to-event type of endpoints 
at the time of their last patient contact [CONTACT_38069]. Th e overall response 
(CR+PR) rate will also be summarized.  
10.4.2  Safety  Analyses  
 
Safety endpoints will be analyzed as summary statistics during treatment and/or as change scores from 
baselines such as shift tables. AEs will be coded using Medical Dictionary for R egulatory Activities 
(MedDRA), calculated (counted once only for a given participant), presented (severity, frequency, and the 
relationship of AEs to study agent will be presented by [CONTACT_38070][INVESTIGATOR_14839]). 
The information reporte d about each AE will be the start date, stop date, severity, relationship, outcome, 
and duration). AEs leading to premature discontinuation from the study and serious treatment AEs will be 
presented either in an independent table or a listing.  
10.4.3  Baseline Des criptive  Statistics  
 
Study cohorts and groups will be compared on baseline characteristics, including demographics and 
laboratory measurements, using descriptive statistics.  
10.4.4  Planned Interim  Analyses  
 
[IP_ADDRESS]  Safety  Review  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 40 of 43  
 The safety analysis will be conducted on the Safety Population. The following safety parameters will be 
evaluated: adverse events, clinical laboratory tests, physical examinations, vital signs, ECOG  performance 
status, ECGs, radiographic or other imaging assessments , immune safety, and immunogenicity. All safety 
parameters will be summarized using descriptive  statistics.  
• Adverse  Events  
Treatment- emergent adverse events (TEAEs) are defined as signs or symptoms that emerge during 
treatment or within [ADDRESS_39965] exposure of unk nown etiology and is consistent 
with an immune -mediated mechanism.  
All AEs recorded during the study will be summarized by [CONTACT_38071]. The 
incidence of TEAEs will be summarized by [CONTACT_6764], preferred term, verbatim of adverse ev ent, 
intensity (based on CTCAE Version 5.0 grade), and relationship to the Investigational Product  
• Vital Signs  
The observed vital signs at each visit and the change from baseline to each post -baseline visit will be 
summarized by [CONTACT_38071].  
• Physical  Examination  
Abnormal findings in the physical examination will be summarized by [CONTACT_38072].  
• Clinical Laboratory  Tests  
Clinical laboratory test values outside the normal range and clinically sig nificant abnormal range will 
be flagged in the data listing. Laboratory data will be summarized by [CONTACT_38073] (baseline 
to notable post- baseline visit). The change from baseline will be summarized using descriptive  
statistics.  
• ECOG  
The data observed from ECOG performance status will be summarized appropriately.  
• Other Safety  Evaluations  
The results of ECGs, radiographic or other imaging assessments, immune safety tests, and 
immunogenicity will be summarized appropriately.  
10.4.[ADDRESS_39966] will be reported descriptively. A fresh tumor 
biopsy will be utilized to quantitatively measure the level of immune response to Emm55 expression.  
Subsequent  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 41 of 43  
 assays will be to measure immune cell subsets within peripheral blood and biopsy samples. If additional 
material is available after these preliminary assays, further immunological assessment of available material will be performed as suggested by [CONTACT_38074] -clinical work.  
10.5 Sample  Size 
 
The intent of this study is to enroll six evaluable patients to assess the safety of IFx- Hu2.0 as a 
monotherapy. The sample size has the following precision for estimation of DLT rates for estimating 
ranging from 0.1 to 0.5. A D LT is defined as an adverse event equal to or greater than grade 3, definitely 
related to the investigational agent within a 4 week period. Precision is measured by 1 -sided 95% upper 
confidence limit on the estimated DLT rate via exact binomial distributio n. For example, if no DLT is 
observed in patients on IFX -Hu 2.0, then the true underlying DLT rate is lower than 0.393 with 95% 
confidence.  
 
11 SOURCE  DOCUMENTS AND  ACCESS  TO SOURCE 
DATA/DOCUMENTS 
Moffitt Cancer Center will maintain appropriate medical and re search records for this trial in compliance 
with ICH E6 and regulatory and institutional requirements for the protection of confidentiality of 
participants.  
Source data are all information, original records of clinical findings, observations, or other acti vities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, participant’s memory aids or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_24440], microfiches, photographic negatives, microfilm or magnetic media, x - 
rays, and participant files and records kept at the pharmacy, at the laboratories, and medico -technical 
departments involved in the clinical trial.  
To ensure that anyone who would access the patient medical record has adequate knowledge that the 
patient is participating in a clinical trial, it is not acceptable for the CRF to be the only record of a patient’s 
participation in the study. CRF entries must contain information which is also recorded elsewhere in the patient’s medica l record.  
 
12 QUALITY  ASSURANCE AND  QUALITY  CONTROL  
Quality Control (QC) procedures will be implemented beginning with the Data Management (DM) provider 
data entry system and data QC checks that will be run on the database will be generated. Any missing data 
or data anomalies will be communicated to the site for clarification/resolution.  
Following written standard operating procedures, the monitor will verify that the clinical trial is 
conducted,  and data are generated, documented (recorded), and reported in co mpliance with the 
protocol, GCP, and the applicable regulatory requirements.  
IFX-HU2.0  
Clinical Study  Protocol: CM [ADDRESS_39967] access to all trial- related sites, source data/documents, and 
reports, for the purpose of monitoring and auditing by [CONTACT_38075]’s designee and for 
inspection by [CONTACT_3482].  
 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
13.[ADDRESS_39968]  
 
The PI [INVESTIGATOR_38044] 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
13.[ADDRESS_39969]  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must 
be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All changes to the consent form 
will be IRB approved; a determination will be made regarding whether previously consented participants 
need to be re -consented.  
13.3 Informed Consent  Process  
 
13.3.1  Consent/Assent  and Other  Informational  Documents  Provided  to Participants  
 
Consent forms describing in detail the study agent, study procedures, and risks will be given to the 
participant and written documentation of informed consent is required prior to starting 
intervention/administering study product.  
13.3.2  Consent Procedures and  Documentation  
 
Informed consent is a process that is initiated prior to the individual’s agreement to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible 
benefits of participatio n will be provided to the participants and their families. Consent forms will be IRB-
approved , and the participant will be asked to read and review the document. The investigator will explain 
the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study  and of their rights as research participants. Participants will have the opportunity to carefully 
review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates o r think about it prior to agreeing to participate. The 
participant will sign the informed consent document prior to any procedures being done specifically for the study.  
When, in the judgment of the chairman of the local IRB, the Investigator, and/or the Sponsor, an amendment 
to the protocol substantially alters the study design and/or increases the potential risk to the subject, the 
currently approved written ICF will req uire similar modification  and IRB approval .  In such cases, repeat 
informed consent will be obtained from subjects enrolled in the study before continued participation under 
the new amendment.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 43 of 43  
 The FDA has  recently issued guidance to address the Coronavirus Disease 2019 (COVID -19) public health 
emergency. If the trial participant  cannot  return to the study site, the consent form may be sent to the 
trial participant  (or representative who can provide the document to the trial partici pant)  by [CONTACT_6972] ,  
email or mail, and the consent interview may then be conducted by [CONTACT_38076]. After the consent discussion, the trial participant can 
sign and date the consent  form. Options for returning the document to the clinical investigator may 
include facsimile, a photographic image sent thro ugh electronic means, scanning the consent form and 
returning it through a secure email account, or posting it to a secure internet address . Alternatively, the 
trial participant may bring the signed and dated consent form to his/her next visit to the clinical site  or 
mail it to the clinical investigator. The medical records  for each trial participant must document the 
method used for o btaining consent and that informed consent was obtained prior to their continued 
participation in the trial. T he person signing the consent form must receive a copy of the consent form. 
Although FDA regulations do not require the trial participant’s copy to be a signed copy, FDA recommends that a copy of the signed consent form be provided.  The participants may wi thdraw consent at any time 
throughout the course of the trial. The  rights  and welfare  of the participants  will be protected  by 
[CONTACT_38077].  
13.3.[ADDRESS_39970] all documents and records required to be maintained by  [CONTACT_093], including but not limited 
to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The 
clinical study site will permit access to such records.  
The study participant’s contact [CONTACT_38078]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_38079].  
Data will be captured in paper CRFs provided by [CONTACT_38080] . The CRFs will be reviewed periodically by [CONTACT_3211] -
designated monitors throughout the conduct of the trial per the clinical  trial agreement and the PBRS 
Global Monitoring Plan. This review will include source data verification utilizing research subjects’ 
medical  records.  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be stored at PBRS . The study systems used by [CONTACT_38081]. The DM provider ’s system will store subject data in a [ADDRESS_39971]  KEEPI[INVESTIGATOR_38045]-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 44 of 43  
 14.1 Data Collection  and Management  Responsibilities  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. 
The PI [INVESTIGATOR_19760], completeness, legibility, and timeliness of the data 
reported.  
All source documents will be  completed in a neat, legible manner to ensure accurate interpretation of 
data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, 
cross out the original entry with a single line, and initial and date the chan ge. DO NOT ERASE, OVERWRITE, 
OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Paper CRFs will be provided for use as data collection documents and maintained for recording data for 
each participant enrolled in the study. Data derived from source documents and reported in the CRF  
should be consistent with the source documents , or the discrepancies should be explained and captured 
in a query and maintained with the paper CRF.  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be captured on paper CRFs provided by [CONTACT_38080] . 
14.2 Study Records  Retention  
 
No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be 
retained.  
14.3 Protocol  Deviations  
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or current clinical  practice 
requirements at Moffitt Cancer Center. The noncompliance may be either on the part of the participant, 
the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by 
[CONTACT_5753] i mplemented  promptly.  
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section  5.1.1  
• 5.[ADDRESS_39972] be sent to the local IRB per their guidelines. The site PI/study staff is responsible for 
knowing and adhering to their IRB requirements.  
14.4 Publication and Data Sharing  Policy  
 
This study will adhere with the details set forth in the clinical trial agreement between Morphogenesis, 
Inc. (sponsor) and Moffitt Cancer Center (clinical site) as it pertains to the sharing and publication of clinical 
research data.  
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 45 of 43  
 The International Committee of Medical Journal  Editors (ICMJE) member journals ha s adopted  a clinical 
trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research 
project that prospectively assigns human subjects to intervention or concurrent compar ison or control 
groups to study the cause -and-effect relationship between a medical intervention and a health outcome. 
Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care 
changes, and the like. Health o utcomes include any biomedical or health -related measures obtained in 
patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy and 
the Section 801 of the Food and Drug Administration  (FDA)  Amendments Act of 2007 requires that all 
clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_38082].  
15 STUDY  ADMINISTRATION  
15.1 Study  Leadership  
 
Study leadership wi ll be the responsibility of the PI [INVESTIGATOR_38046]/or its representative. Study leadership will meet periodically as needed.  
This trial will be monitored continuously by [CONTACT_978], who will be assisted by [CONTACT_38083].  
 
[ADDRESS_39973] 
that i s appropriate to their participation in the trial.  
17 LITERATURE REFERENCES  
Chen, D. S. and I. Mellman (2013). "Oncology meets immunology: the cancer -immunity cycle." Immunity  
39(1): 1 -10. 
 
Dale, J. B., P. R. Smeesters, H. S. Courtney, T. A. Pen found, C. M. Hohn, J. C. Smith and J. Y. Baudry 
(2017).  "Structure -based  design  of broadly  protective  group  a streptococcal  M protein -based  vaccines." 
Vaccine  35(1):  19-26. 
 
Dinkla, K., D. P. Nitsche -Schmitz, V. Barroso, S. Reissmann, H. M. Johansson, I. M. Frick, M. Rohde and G.  
S. Chhatwal (2007). "Identification of a streptococcal octapeptide motif involved in acute rheumatic 
fever." J Biol Chem  282(26): [ZIP_CODE]- [ZIP_CODE].  
 
Glikin,  G. C. and L. M. Finocchiaro  (2014).  "Clinical  trials  of immunoge ne therapy  for spontaneous  tumors 
in companion animals." ScientificWorldJournal 2014 : 718520.  
 
Nitsche -Schmitz,  D. P., M. Rohde  and G. S. Chhatwal (2007).  "Invasion  mechanisms  of Gram -positive 
pathogenic cocci." Thromb Haemost  98(3): 488-496.  
 
IFX-HU2.0  
Clinical Study  Protocol: CM 2017 -01 Morphogenesis,  Inc. 
IND [ZIP_CODE], SN  0000  
Confidential  Page 46 of 43  
 Ramiya,  V. K., M. M. Jerald,  P. D. Lawman  and M. J. Lawman  (2014).  "Autologous  tumor  cells  engineered 
to express bacterial antigens." Methods Mol Biol 1139 : 243-257.  
 
Reissmann,  S., C. M. Gillen,  M. Fulde,  R. Bergmann,  A. Nerlich,  R. Rajkumari,  K. N. Brahmadathan,  G. S. 
Chhatwal and D. P. Nitsche -Schmitz (2012). "Region -specific and worldwide distribution of collagen - 
binding M proteins  with  PARF  motifs  among  human  pathogenic  streptococcal isolates."  PLoS  One 7(1): 
e30122.  